GL Biochem (Shanghai): difference between revisions
Diff·revision 44 → 45·13:54, 8 Mar 2025
Difference between revision 44 and revision 45 of GL Biochem (Shanghai). 5 lines changed; the page grew by 809 bytes.
| Revision 44 — 09:35, 28 Feb 2025 GroupBuyGalen (talk) fix category — parent was wrong 9,261 bytes +138 | Revision 45 — 13:54, 8 Mar 2025 BlankVialBo (talk) lead should summarise the body, not add to it 10,070 bytes +809 | ||
|---|---|---|---|
| 60 | Amino acid analysis is the technique that establishes [[Peptide content|peptide content]] as a mass fraction rather than inferring it, and its presence on a certificate answers the question that a purity figure alone leaves open.{{r|usp1503}} Its appearance on certificates from an upstream supplier and its near-absence from retail certificates is the clearest illustration on this wiki of the documentary difference between the two markets. | 60 | Amino acid analysis is the technique that establishes [[Peptide content|peptide content]] as a mass fraction rather than inferring it, and its presence on a certificate answers the question that a purity figure alone leaves open.{{r|usp1503}} Its appearance on certificates from an upstream supplier and its near-absence from retail certificates is the clearest illustration on this wiki of the documentary difference between the two markets. |
| 61 | 61 | ||
| + | 62 | The reports remain individual samples not drawn under a documented [[Chain of custody|chain of custody]], and the general limitation applies.{{r|reports,iso17025}} | |
| + | 63 | ||
| 62 | == Reception == | 64 | == Reception == |
| 63 | The PeptidePedia tally records 1,962 self-reported submissions to July 2026 — the second-largest count in this group, consistent with a longer history and a wider customer base. Recurring positive themes are documentation completeness and synthesis of difficult sequences; recurring complaints concern lead times and minimum order quantities that suit a laboratory rather than an individual purchaser.{{r|tally}} Self-selected; reception rather than quality.{{r|tally}} | 65 | The PeptidePedia tally records 1,962 self-reported submissions to July 2026 — the second-largest count in this group, consistent with a longer history and a wider customer base. Recurring positive themes are documentation completeness and synthesis of difficult sequences; recurring complaints concern lead times and minimum order quantities that suit a laboratory rather than an individual purchaser.{{r|tally}} Self-selected; reception rather than quality.{{r|tally}} |
| 64 | 66 | ||
| + | 67 | '''Disclosure.''' GL Biochem is one of the organisations whose labelled supporter notices appear on this site. Supporters have no editorial input, are not consulted on article content, and receive no consideration in article space; the arrangement is described at [[Project:Conflict of interest]]. This article is subject to the same sourcing and neutrality requirements as every other, and the disclosure is stated here because a reader is entitled to weigh it. | |
| + | 68 | ||
| 65 | == References == | 69 | == References == |
| 66 | {{reflist}} | 70 | {{reflist}} |
| ⋮ | ⋮ | ||
| 70 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | 74 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> |
| 71 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | 75 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> |
| + | 76 | <ref name="iso17025">ISO/IEC 17025:2017, ''General requirements for the competence of testing and calibration laboratories''. International Organization for Standardization.</ref> | |
| 72 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 77 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 73 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> | 78 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> |